Salazar, Juan CCahn, PedroYogev, RamNegra, Marinella DellaCastelli-Gattinara, GuidoFortuny, ClaudiaFlynn, Patrica MGiaquinto, CarloRuan, Ping KSmith, M ElizabethMikl, JaromirJelaska, Antefor the PACTG 1051/BI Study Team2024-05-232024-05-232008-09-12https://doi.org/10.1097/qad.0b013e32830c481bhttps://repositorio.huesped.org.ar/handle/123456789/1318Fil: Cahn P. Fundación Huésped, Buenos Aires; ArgentinaObjective: To evaluate the efficacy, safety and tolerability of ritonavir-boosted tipranavir (TPV/r) in HIV-1-infected pediatric patients. Design: Open-label randomized pediatric trial (1182.14/PACTG1051) comparing TPV/r at two doses including an optimized background regimen. Methods: HIV-1-infected patients (2–18 years) with plasma viral load 1500 copies/ml or more were randomized to TPV/r 290/115 or 375/150 mg/m2 twice-daily oral solution and optimized background regimen. Week 48 efficacy, safety and tolerability results were evaluated. Results: Children (n = 115; 97% treatment experienced) were randomized to low or high dose therapy. Eighty-eight remained on-treatment through 48 weeks. Baseline characteristics were similar between dose groups. At study entry, half of the HIV-1 isolates were resistant to all protease inhibitors. At 48 weeks, 39.7% low-dose and 45.6% high-dose TPV/r recipients had viral load less than 400 copies/ml and 34.5 and 35.1%, respectively, achieved viral load less than 50 copies/ml. Vomiting, cough and diarrhea were the most frequent adverse events. Grade 3 alanine aminotransferase elevations were observed in 6.3% of patients. No grade 4 alanine aminotransferase or grade 3/4 aspartate aminotransferase elevations were reported. Conclusions: TPV/r achieved a sustained virologic response, showed a good safety profile and was well tolerated at either dose. In pediatric patients with high baseline resistance profiles, high-dose TPV/r tended to demonstrate a better sustained response.application/pdfopenAccessHIV-1ChildAdolescentRitonavirArticulo